GLPwatch
Soliqua for Parkinson's disease
lixisenatide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCSoliqua (lixisenatide) is not FDA-approved for Parkinson's disease, and any use for this condition is off-label or investigational. Research suggests lixisenatide may have neuroprotective effects in Parkinson's disease models, but clinical efficacy remains under investigation.
AI summary of the sources below.
| Drug | Soliqua (lixisenatide) |
|---|---|
| Condition | Parkinson's disease |
| Approval status | Investigational / off-label |
| Research papers | 5 |
Soliqua is not FDA-approved for parkinson's disease; the research below reflects investigational or off-label study only.
Research on lixisenatide for parkinson's disease (5)
- Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis.
- Trial of Lixisenatide in Early Parkinson's Disease.
- Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
- Lixisenatide in early parkinson's disease: efficacy, safety, and future directions: a correspondence.
- Are glucagon-like peptide-1 (GLP-1) receptor agonists useful in treating Parkinson's disease (PD)? Does the clinical trial with lixisenatide add anything?